NSABP B-43: A Phase III Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

March 14, 2009
5520-CTO
Cancer - Breast

Patients must be female; Patients must be 18 years of age or older; On histologic examination, the tumor must be ductal carcinoma in situ (DCIS) (Patients with mixed DCIS and lobular carcinoma in situ [LCIS] are eligible; The interval between the last surgery for excision of DCIS (lumpectomy or reexcision of lumpectomy margins) and randomization must be no more than 120 days.

Open
Tiffany Pearce